Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG. Laubach JP, et al. Among authors: wrobel t. Lancet Oncol. 2021 Jan;22(1):142-154. doi: 10.1016/S1470-2045(20)30680-X. Epub 2020 Dec 7. Lancet Oncol. 2021. PMID: 33301738 Clinical Trial.
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
Hus I, Jawniak D, Gorska-Kosicka M, Butrym A, Dzietczenia J, Wrobel T, Grzegorz M, Lech-Maranda E, Warzocha K, Waszczuk-Gajda A, Jedrzejczak WW, Krawczyk-Kulis M, Kyrcz-Krzemien S, Poplawska L, Walewski J, Dmoszynska A. Hus I, et al. Among authors: wrobel t. Chemotherapy. 2013;59(4):280-9. doi: 10.1159/000357468. Epub 2014 Jan 21. Chemotherapy. 2013. PMID: 24457828
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W. Younes A, et al. Among authors: wrobel t. Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11. Lancet Haematol. 2019. PMID: 30642819 Clinical Trial.
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Topp MS, Eradat H, Florschütz A, Hochhaus A, Wrobel T, Walewski J, Knopinska-Posluszny W, Kanate AS, Lech-Maranda E, Brunnberg U, Chitra S, Nielsen TG, Sellam G, Shivhare M, Lossos IS. Topp MS, et al. Among authors: wrobel t. J Cancer Res Clin Oncol. 2023 Feb;149(2):811-817. doi: 10.1007/s00432-021-03847-5. Epub 2022 Feb 18. J Cancer Res Clin Oncol. 2023. PMID: 35182224 Free PMC article.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
Mateos MV, Rigaudeau S, Basu S, Spicka I, Schots R, Wrobel T, Cook G, Beksac M, Gries KS, Kudva A, Tromp B, Van Rampelbergh R, Pei H, Wroblewski S, Carson R, Delioukina M, White D. Mateos MV, et al. Among authors: wrobel t. J Oncol Pharm Pract. 2023 Jul;29(5):1172-1177. doi: 10.1177/10781552221103551. Epub 2022 Sep 6. J Oncol Pharm Pract. 2023. PMID: 36067063 Clinical Trial.
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Walewski J, Kraszewska E, Mioduszewska O, Romejko-Jarosińska J, Hellmann A, Czyz J, Hołowiecki J, Kopera M, Grosicki S, Komarnicki M, Rumianowski L, Kuliczkowski K, Wróbel T, Dwilewicz-Trojaczek J, Robak T, Warzocha K, Załuski J, Wójcik E, Dmoszyńska A, Walter-Croneck A; Polish Lymphoma Research Group. Walewski J, et al. Among authors: wrobel t. Med Oncol. 2001;18(2):141-8. doi: 10.1385/mo:18:2:141. Med Oncol. 2001. PMID: 11778760 Clinical Trial.
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study.
Jurczak W, Szmit S, Sobociński M, Machaczka M, Drozd-Sokołowska J, Joks M, Dzietczenia J, Wróbel T, Kumiega B, Zaucha JM, Knopińska-Posłuszny W, Spychałowicz W, Prochwicz A, Drohomirecka A, Skotnicki AB. Jurczak W, et al. Among authors: wrobel t. Int J Cardiol. 2013 Oct 15;168(6):5212-7. doi: 10.1016/j.ijcard.2013.08.033. Epub 2013 Aug 15. Int J Cardiol. 2013. PMID: 23998543
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Czechowska E, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Komarnicki MA. Dytfeld D, et al. Among authors: wrobel t. Oncotarget. 2016 Aug 30;7(35):56726-56736. doi: 10.18632/oncotarget.11059. Oncotarget. 2016. PMID: 27527861 Free PMC article.
305 results